Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-044-4 | CAS number: 28472-97-1
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: Assessment of toxicokinetic behaviour
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well documented report which meets basic scientific principles
Data source
Reference
- Reference Type:
- other:
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- The toxicokinetic behaviour of diisodecyl azelate (DIA) was assessed. The OECD QSAR Application Toolbox was used to make a qualitative prediction of oral absorption and of the metabolites formed in liver, skin and gastrointestinal tract. The Danish QSAR Database was used to predict dermal and oral bioavailability of DIA. The fate of these metabolites is predicted on the basis of their chemical structure based on expert judgement.
- GLP compliance:
- no
Test material
- Reference substance name:
- Diisodecyl azelate
- EC Number:
- 249-044-4
- EC Name:
- Diisodecyl azelate
- Cas Number:
- 28472-97-1
- Molecular formula:
- Main component: C29H56O4
- IUPAC Name:
- C9-11 branched alcohols , C10 rich diesters with nonanedioic acid
- Details on test material:
- - Name of test material (as cited in study report): diisodecyl azelate
- Analytical purity: no data
Constituent 1
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- DIA is predicted to be bioavailable via the oral route but is very poorly absorbed via skin.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- DIA is expected to undergo stepwise hydrolysis of the ester bonds yielding azelaic acid and isodecanol. Both azelaic acid and isodecanol feed into the physiological process of fatty acid oxidation and subsequent metabolic pathways, finally leading to expiration as CO2. A metabolic pathway for DIA was proposed.
Tissue accumulation can be excluded.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
